Sign inJoin free

Watch / Stock Selection

UBS is backing CSL's recovery

11 Nov 20266:26

UBS is backing CSL's recovery

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • UBS has lifted its CSL price target to $225, arguing the business is becoming reliable again under interim CEO Gordon Naylor.

  • Lower plasma collection costs and a new fractionation system could support a sustained recovery in gross margins.

  • The incoming CEO and ongoing weakness in China's albumin market remain key risks to the recovery.

CSL is working to rebuild investor confidence after a difficult period. UBS head of Australian healthcare research David Lowe says the core plasma business is returning to the consistency that historically made it a reliable growth story, giving the company greater visibility over its earnings.

Demand for immunoglobulin has moderated to mid-single-digit growth, while selling prices have largely stabilised. However, lower plasma collection costs and a planned shift to a new fractionation system could provide a further lift to yields, supporting gross margin recovery over the coming years.

UBS has raised its price target to $225, seeing greater value in CSL's defensive growth profile. But the leadership transition remains important, while excess albumin inventory in China could keep pressure on prices for another year. Longer term, investors will be watching the rebuild of CSL's R&D pipeline and the benefits of its new fractionation infrastructure.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy